Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Clin Sleep Med. 2011 Oct 15;7(5 Suppl):S9-11. doi: 10.5664/JCSM.1342.
This review will focus on the evaluation of biomarkers and surrogate endpoints in chronic disease risk with a focus on cardiovascular disease. It provides an example of how identification of relevant biomarkers might be useful in sleep research and clinical care. Much of this review is derived from work performed by the Institute of Medicine (IOM) Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease (see footnote in the Acknowledgments). This discussion will review the committee charge, definitions of biomarkers and other endpoints, biomarker evaluation framework, case studies of representative biomarkers, recommendations, and conclusions.
这篇综述将重点关注慢性病风险的生物标志物和替代终点的评估，重点是心血管疾病。它提供了一个如何在睡眠研究和临床护理中识别相关生物标志物的例子。本综述的大部分内容源自医学研究所（IOM）慢性病生物标志物和替代终点资格认定委员会的工作（见致谢中的脚注）。本讨论将回顾委员会的任务、生物标志物和其他终点的定义、生物标志物评估框架、有代表性的生物标志物案例研究、建议和结论。
